JP2018522887A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522887A5 JP2018522887A5 JP2018501155A JP2018501155A JP2018522887A5 JP 2018522887 A5 JP2018522887 A5 JP 2018522887A5 JP 2018501155 A JP2018501155 A JP 2018501155A JP 2018501155 A JP2018501155 A JP 2018501155A JP 2018522887 A5 JP2018522887 A5 JP 2018522887A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- hpv
- subject
- antibody according
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022169277A JP2023024973A (ja) | 2015-07-14 | 2022-10-21 | 免疫チェックポイント阻害剤を使用する癌の処置法 |
| JP2025106098A JP2025138726A (ja) | 2015-07-14 | 2025-06-24 | 免疫チェックポイント阻害剤を使用する癌の処置法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562192396P | 2015-07-14 | 2015-07-14 | |
| US62/192,396 | 2015-07-14 | ||
| PCT/US2016/042297 WO2017011666A1 (en) | 2015-07-14 | 2016-07-14 | Method of treating cancer using immune checkpoint inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022169277A Division JP2023024973A (ja) | 2015-07-14 | 2022-10-21 | 免疫チェックポイント阻害剤を使用する癌の処置法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018522887A JP2018522887A (ja) | 2018-08-16 |
| JP2018522887A5 true JP2018522887A5 (enExample) | 2019-08-22 |
Family
ID=56551000
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018501155A Withdrawn JP2018522887A (ja) | 2015-07-14 | 2016-07-14 | 免疫チェックポイント阻害剤を使用する癌の処置法 |
| JP2022169277A Pending JP2023024973A (ja) | 2015-07-14 | 2022-10-21 | 免疫チェックポイント阻害剤を使用する癌の処置法 |
| JP2025106098A Pending JP2025138726A (ja) | 2015-07-14 | 2025-06-24 | 免疫チェックポイント阻害剤を使用する癌の処置法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022169277A Pending JP2023024973A (ja) | 2015-07-14 | 2022-10-21 | 免疫チェックポイント阻害剤を使用する癌の処置法 |
| JP2025106098A Pending JP2025138726A (ja) | 2015-07-14 | 2025-06-24 | 免疫チェックポイント阻害剤を使用する癌の処置法 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US10544224B2 (enExample) |
| EP (3) | EP3858859B1 (enExample) |
| JP (3) | JP2018522887A (enExample) |
| KR (2) | KR20250065936A (enExample) |
| CN (1) | CN107922502A (enExample) |
| CY (1) | CY1123993T1 (enExample) |
| DK (2) | DK3858859T3 (enExample) |
| ES (2) | ES2855798T3 (enExample) |
| FI (1) | FI3858859T3 (enExample) |
| HR (2) | HRP20210399T1 (enExample) |
| HU (1) | HUE053966T2 (enExample) |
| LT (2) | LT3322731T (enExample) |
| PL (1) | PL3322731T3 (enExample) |
| PT (2) | PT3858859T (enExample) |
| RS (2) | RS67652B1 (enExample) |
| SI (2) | SI3858859T1 (enExample) |
| SM (2) | SMT202100131T1 (enExample) |
| WO (1) | WO2017011666A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| MA42971A (fr) | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
| EP3288980B1 (en) | 2015-04-28 | 2021-03-10 | Bristol-Myers Squibb Company | Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody |
| WO2016176503A1 (en) | 2015-04-28 | 2016-11-03 | Bristol-Myers Squibb Company | Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody |
| DK3303394T3 (da) | 2015-05-29 | 2020-07-06 | Agenus Inc | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf |
| JP6786529B2 (ja) * | 2015-06-29 | 2020-11-18 | バイオメッド バレー ディスカバリーズ，インコーポレイティド | Ｌｐｔ−７２３と免疫チェックポイント阻害剤との組み合わせおよび処置の方法 |
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| DK3858859T3 (da) | 2015-07-14 | 2025-12-15 | Bristol Myers Squibb Co | Fremgangsmåde til behandling af kræft under anvendelse af en immun checkpointinhibitor; antistof som binder til programmeret død-1 receptor (pd-1) eller programmeret død ligand 1 (pd-l1) |
| MX392711B (es) | 2015-08-11 | 2025-03-24 | Wuxi Biologics Ireland Ltd | Anticuerpos anti-pd-1 novedosos. |
| JP6869987B2 (ja) | 2015-09-01 | 2021-05-12 | アジェナス インコーポレイテッド | 抗ｐｄ−１抗体及びその使用方法 |
| EP3364949A4 (en) * | 2015-10-22 | 2019-07-31 | ModernaTX, Inc. | CANCER VACCINES |
| US11072657B2 (en) * | 2015-11-18 | 2021-07-27 | Bristol-Myers Squibb Company | Treatment of lung cancer using a combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody |
| CN108697794A (zh) * | 2015-12-17 | 2018-10-23 | 诺华股份有限公司 | C-met抑制剂和抗pd-1抗体分子的组合及其用途 |
| WO2017157882A1 (en) | 2016-03-14 | 2017-09-21 | Université Catholique de Louvain | Serine biosynthetic pathway inhibitors |
| EP4650005A3 (en) * | 2016-07-15 | 2026-01-28 | Viracta Subsidiary, Inc. | Histone deacetylase inhibitors for use in immunotherapy |
| BR112019006504A2 (pt) * | 2016-10-06 | 2019-06-25 | Pfizer Inc. | regime de dosagem de avelumabe para o tratamento de câncer |
| IL307242B1 (en) | 2016-12-07 | 2026-07-01 | Agenus Inc | Anti-CTLA-4 antibodies and methods of using them |
| CN110300599B (zh) | 2016-12-07 | 2024-07-02 | 艾吉纳斯公司 | 抗体和其使用方法 |
| CN110914302A (zh) | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| WO2018226529A1 (en) | 2017-06-05 | 2018-12-13 | The Regents Of The University Of Michigan | Complexes for delivery of antigenic peptides |
| US12668635B1 (en) | 2017-11-21 | 2026-06-30 | Arcus Biosciences, Inc. | Methods of treating solid tumors using an anti-PD-1 antibody or a fragment thereof |
| CN111868263A (zh) * | 2018-01-12 | 2020-10-30 | 格瑞尔公司 | 分析病毒核酸的方法 |
| CN119792515A (zh) * | 2018-02-13 | 2025-04-11 | 默沙东有限责任公司 | 用抗pd-1抗体和抗ctla-4抗体治疗癌症的方法 |
| WO2019175328A1 (en) | 2018-03-14 | 2019-09-19 | Imba - Institut Für Molekulare Biotechnologie Gmbh | Bh4pathwayactivationandusethereoffortreatingcancer |
| EP3774911A1 (en) * | 2018-03-30 | 2021-02-17 | Bristol-Myers Squibb Company | Methods of treating tumor |
| WO2019236901A1 (en) | 2018-06-06 | 2019-12-12 | The Regents Of The University Of California | Estrogen receptor inhibitors and uses therof |
| US20210255168A1 (en) * | 2018-06-13 | 2021-08-19 | King Faisal Specialist Hospital & Research Centre | A method of precision cancer therapy |
| BR112021008117A2 (pt) * | 2018-10-31 | 2021-08-31 | Genentech, Inc. | Método e medicamento para tratamento de câncer que não responde ao inibidor de sinalização pd-1/pd-l1 |
| CN113365659B (zh) * | 2019-01-31 | 2023-08-18 | 正大天晴药业集团股份有限公司 | 抗pd-l1抗体治疗头颈癌的用途 |
| DE102019208563B4 (de) | 2019-06-12 | 2026-03-26 | Volkswagen Aktiengesellschaft | Optischer Flüssigkeitssensor und elektrisches System zur optischen Detektion von Flüssigkeiten |
| TW202138006A (zh) * | 2019-12-13 | 2021-10-16 | 韓商三星Ｂｉｏｅｐｉｓ股份有限公司 | 穩定之抗-pd1抗體醫藥調配物 |
| JP2023510132A (ja) * | 2019-12-20 | 2023-03-13 | メルク・シャープ・アンド・ドーム・エルエルシー | Ｐｄ－１アンタゴニスト、ｉｌｔ４アンタゴニストおよび化学療法剤の組合せを使用して癌を治療する方法 |
| KR102541413B1 (ko) | 2020-02-06 | 2023-06-12 | 영남대학교 산학협력단 | 면역 체크포인트 억제제 및 ampk 활성화제를 유효성분으로 함유하는 암질환 예방 또는 치료용 조성물 |
| GB2629999B (en) * | 2021-04-21 | 2025-03-26 | Act Therapeutics Ltd | Enhancement of treatment with immunotherapeutic agents |
| KR102779377B1 (ko) | 2022-07-22 | 2025-03-12 | 가톨릭대학교 산학협력단 | 디옥시시코닌 또는 그의 약제학적으로 허용가능한 염을 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물 |
| KR102893442B1 (ko) * | 2022-12-23 | 2025-12-01 | 가톨릭대학교 산학협력단 | 켈레리트린 클로라이드 또는 그의 약제학적으로 허용가능한 염을 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US7727761B2 (en) | 1995-08-01 | 2010-06-01 | Vegenics Limited | Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| DE69829891T2 (de) | 1997-04-07 | 2005-10-06 | Genentech, Inc., South San Francisco | Anti-VEGF Antikörper |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| JP2002536968A (ja) | 1999-01-29 | 2002-11-05 | イムクローン システムズ インコーポレイティド | Ｋｄｒに特異的な抗体およびその使用 |
| ES2539411T3 (es) | 1999-08-23 | 2015-06-30 | Dana-Farber Cancer Institute, Inc. | PD-1, receptor para la B7-4 y su utilización |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| AU2001233027A1 (en) | 2000-01-27 | 2001-08-07 | Genetics Institute, Llc | Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof |
| PT1916001E (pt) | 2002-03-04 | 2011-07-18 | Imclone Llc | Anticorpos humanos específicos para kdr e suas utilizações |
| DE60334303D1 (de) | 2002-07-03 | 2010-11-04 | Tasuku Honjo | Immunpotenzierende zusammensetzungen |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| EP2377555A3 (en) | 2004-11-18 | 2011-11-23 | Imclone LLC | Antibodies against vascular endothelial growth factor receptor-1 |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| DK1907000T4 (da) * | 2005-06-08 | 2020-03-30 | The President And Fellows Of Harvard College | Fremgangsmåder og sammensætninger til behandling af persisterende HIV-infektioner ved hæmning af reaktionsvejen for programmeret celledød 1 (PD-1). |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| WO2007113648A2 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| WO2009060198A1 (en) | 2007-11-09 | 2009-05-14 | Peregrine Pharmaceuticals, Inc. | Anti-vegf antibody compositions and methods |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| EA201500417A1 (ru) | 2008-08-25 | 2015-11-30 | Эмплиммьюн, Инк. | Композиции антагонистов pd-1 и способы применения |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| ES2699965T3 (es) | 2011-03-10 | 2019-02-13 | Provectus Pharmatech Inc | Una combinación de rosa de bengala y anticuerpo anti-CTLA4 para su uso en el tratamiento del cáncer |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| BR112015007184A2 (pt) | 2012-10-02 | 2017-08-08 | Bristol Myers Squibb Co | combinação de anticorpos anti-kir e anticorpos anti-pd-1 para tratar câncer |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| RS64268B1 (sr) * | 2013-09-20 | 2023-07-31 | Bristol Myers Squibb Co | Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora |
| UA122479C2 (uk) * | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| JP2017515859A (ja) | 2014-05-15 | 2017-06-15 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体と他の抗癌剤の組み合わせを使用する肺癌の処置 |
| CA2949327A1 (en) * | 2014-05-29 | 2015-12-03 | Medimmune Limited | Antagonists of pdl-1 and pd-1 for the treatment of hpv-negative cancers |
| US10354541B2 (en) | 2014-07-02 | 2019-07-16 | Raytheon Bbn Technologies Corporation | Tutor model building system |
| WO2016011357A1 (en) * | 2014-07-18 | 2016-01-21 | Advaxis, Inc. | Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer |
| EP3183269A2 (en) * | 2014-08-22 | 2017-06-28 | Bristol-Myers Squibb Company | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody |
| HRP20201334T1 (hr) * | 2015-04-17 | 2020-11-27 | Bristol-Myers Squibb Company | Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba |
| DK3858859T3 (da) | 2015-07-14 | 2025-12-15 | Bristol Myers Squibb Co | Fremgangsmåde til behandling af kræft under anvendelse af en immun checkpointinhibitor; antistof som binder til programmeret død-1 receptor (pd-1) eller programmeret død ligand 1 (pd-l1) |
-
2016
- 2016-07-14 DK DK20214749.2T patent/DK3858859T3/da active
- 2016-07-14 JP JP2018501155A patent/JP2018522887A/ja not_active Withdrawn
- 2016-07-14 KR KR1020257014642A patent/KR20250065936A/ko active Pending
- 2016-07-14 ES ES16744626T patent/ES2855798T3/es active Active
- 2016-07-14 US US15/210,612 patent/US10544224B2/en active Active
- 2016-07-14 RS RS20251179A patent/RS67652B1/sr unknown
- 2016-07-14 HU HUE16744626A patent/HUE053966T2/hu unknown
- 2016-07-14 DK DK16744626.9T patent/DK3322731T3/da active
- 2016-07-14 EP EP20214749.2A patent/EP3858859B1/en active Active
- 2016-07-14 KR KR1020187003984A patent/KR20180027576A/ko not_active Ceased
- 2016-07-14 SI SI201631932T patent/SI3858859T1/sl unknown
- 2016-07-14 SI SI201631090T patent/SI3322731T1/sl unknown
- 2016-07-14 SM SM20210131T patent/SMT202100131T1/it unknown
- 2016-07-14 HR HRP20210399TT patent/HRP20210399T1/hr unknown
- 2016-07-14 HR HRP20251434TT patent/HRP20251434T1/hr unknown
- 2016-07-14 FI FIEP20214749.2T patent/FI3858859T3/fi active
- 2016-07-14 WO PCT/US2016/042297 patent/WO2017011666A1/en not_active Ceased
- 2016-07-14 ES ES20214749T patent/ES3055227T3/es active Active
- 2016-07-14 EP EP25203723.9A patent/EP4679094A3/en active Pending
- 2016-07-14 SM SM20260008T patent/SMT202600008T1/it unknown
- 2016-07-14 EP EP16744626.9A patent/EP3322731B1/en not_active Revoked
- 2016-07-14 RS RS20210284A patent/RS61532B1/sr unknown
- 2016-07-14 LT LTEP16744626.9T patent/LT3322731T/lt unknown
- 2016-07-14 PT PT202147492T patent/PT3858859T/pt unknown
- 2016-07-14 PL PL16744626T patent/PL3322731T3/pl unknown
- 2016-07-14 LT LTEP20214749.2T patent/LT3858859T/lt unknown
- 2016-07-14 CN CN201680052756.8A patent/CN107922502A/zh active Pending
- 2016-07-14 PT PT167446269T patent/PT3322731T/pt unknown
-
2019
- 2019-12-05 US US16/704,913 patent/US20200190198A1/en not_active Abandoned
-
2021
- 2021-03-26 CY CY20211100264T patent/CY1123993T1/el unknown
-
2022
- 2022-10-21 JP JP2022169277A patent/JP2023024973A/ja active Pending
-
2023
- 2023-07-26 US US18/359,696 patent/US20240124592A1/en not_active Abandoned
-
2025
- 2025-06-24 JP JP2025106098A patent/JP2025138726A/ja active Pending
-
2026
- 2026-01-23 US US19/458,420 patent/US20260226171A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210399T1 (hr) | Postupak liječenja raka primjenom inhibitora imunološke kontrolne točke; antitijelo koje se vezuje za receptor programirane smrti-1 (pd-1) ili ligand programirane smrti-1 (pd-l1) | |
| JP2018515474A5 (enExample) | ||
| Hude et al. | The emerging role of immune checkpoint inhibition in malignant lymphoma | |
| JP2018514550A5 (enExample) | ||
| KR102333658B1 (ko) | 비-소세포 폐암을 치료하기 위한 항-ｂ7-ｈ1 및 항-ｃｔｌａ-4 항체 | |
| MX2020008446A (es) | Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4. | |
| JP2019503387A5 (enExample) | ||
| IL278423B1 (en) | Pd-1 / pd-l1 inhibitors for the treatment of cancer | |
| JP2018500332A5 (enExample) | ||
| Vici et al. | Emerging biological treatments for uterine cervical carcinoma | |
| JP2016528195A5 (enExample) | ||
| MX2024013016A (es) | Anticuerpos anti-pd1 para usarse en el tratamiento del cancer | |
| MX2024000780A (es) | Anticuerpo anti-pd-1 para usarse en el tratamiento de cancer de pulmon. | |
| MX2022014867A (es) | Anticuerpos especificos del receptor de poliovirus humano (rvp). | |
| JP2016525117A5 (enExample) | ||
| CA2886433C (en) | Human monoclonal anti-pd-l1 antibodies and methods of use | |
| JP2017534633A5 (enExample) | ||
| RU2017117664A (ru) | Комбинация | |
| JP2017537090A5 (enExample) | ||
| JP2017524715A5 (enExample) | ||
| JP2022500410A5 (enExample) | ||
| WO2018112407A1 (en) | Antibodies and methods for depleting regulatory b10 cells and use in combination with immune checkpoint inhibitors | |
| JP2019517498A5 (enExample) | ||
| JP2019517504A5 (enExample) | ||
| JP2023525664A (ja) | がんの処置のためのアルファ－２アドレナリン作動性受容体アゴニスト |